期刊
ALLERGY
卷 66, 期 -, 页码 50-52出版社
WILEY
DOI: 10.1111/j.1398-9995.2011.02639.x
关键词
Disease modifying effect; grass allergy immunotherapy tablet; immunological tolerance; sustained efficacy
资金
- ALK-Abello
- Novartis
- Medical Research Council [G1000758B, G1000758] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish
P>We report the sustained efficacy of the SQ-standardized grass allergy immunotherapy tablet Grazax (R) (Phleum pratense 75 000 SQ-T/2,800 BAU, ALK, Denmark) from a 5-year randomized, double-blind, placebo-controlled phase III trial. Adults with moderate-to-severe grass pollen allergy inadequately controlled by symptomatic medications were followed for 2 years after the completion of 3 years of treatment. The active group demonstrated a 31% reduction in median rhinoconjunctivitis symptom score over the season compared with placebo. Individual symptom scores favoured active treatment. Combined symptom and medication scores demonstrated a 33% reduction in medians with active treatment. Persistent clinical efficacy was accompanied by prolonged increases in allergen-specific IgG(4) antibodies and IgE-blocking factor, confirming clinical and immunological tolerance for at least 2 years after the treatment completion. No safety issues were identified during follow-up.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据